Literature DB >> 8415648

Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer.

W Jiang1, Y J Zhang, S M Kahn, M C Hollstein, R M Santella, S H Lu, C C Harris, R Montesano, I B Weinstein.   

Abstract

We have examined DNA from four human esophageal carcinoma cell lines and 50 primary esophageal carcinomas obtained from China, Italy, and France for amplification of the cyclin D1 gene. We also examined 36 of these 50 carcinomas for expression of the cyclin D1 and retinoblastoma (RB) proteins by immunohistochemistry. We found a 3- to 10-fold amplification of the cyclin D1 gene in 16 of the 50 (32%) tumors and in two of the four cell lines. Cyclin D1 protein was overexpressed in 12 of 13 tumors and the two cell lines that showed gene amplification when compared to normal controls. Studies on RB protein expression indicated that 6 of the 36 (17%) tumor samples examined and one cell line did not show detectable expression of this protein. The tumors and cell lines that had cyclin D1 gene amplification and overexpression exhibited normal levels of expression of RB protein. By contrast, the tumors and cell line that did not appear to express the RB protein did not show amplification of the cyclin D1 gene and expressed only low levels of the cyclin D1 protein (P = 0.03). These results suggest that the inhibitory effect of RB on cell cycle progression can be abrogated during tumor development either by loss of expression of the RB gene or by increased expression of the cyclin D1 gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415648      PMCID: PMC47494          DOI: 10.1073/pnas.90.19.9026

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.

Authors:  C L Rosenberg; E Wong; E M Petty; A E Bale; Y Tsujimoto; N L Harris; A Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

2.  Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers.

Authors:  R F Boynton; P L Blount; J Yin; V L Brown; Y Huang; Y Tong; T McDaniel; C Newkirk; J H Resau; W H Raskind; R C Haggitt; B J Reid; S J Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

3.  Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer.

Authors:  W P Bennett; M C Hollstein; A He; S M Zhu; J H Resau; B F Trump; R A Metcalf; J A Welsh; C Midgley; D P Lane
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

Review 4.  Chromosome 11q13 abnormalities in human cancer.

Authors:  G A Lammie; G Peters
Journal:  Cancer Cells       Date:  1991-11

Review 5.  Tumor suppressor genes.

Authors:  R A Weinberg
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

6.  Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas.

Authors:  E Schuuring; E Verhoeven; W J Mooi; R J Michalides
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

7.  The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner.

Authors:  S Shirodkar; M Ewen; J A DeCaprio; J Morgan; D M Livingston; T Chittenden
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

8.  Human D-type cyclin.

Authors:  Y Xiong; T Connolly; B Futcher; D Beach
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

9.  Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast.

Authors:  D J Lew; V Dulić; S I Reed
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

10.  The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.

Authors:  J A Lees; K J Buchkovich; D R Marshak; C W Anderson; E Harlow
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  77 in total

Review 1.  Cell cycle checkpoints and their inactivation in human cancer.

Authors:  M Molinari
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

2.  Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure.

Authors:  Yu-Jing Zhang; Hui-Chen Wu; Hulya Yazici; Ming-Whei Yu; Po-Huang Lee; Regina M Santella
Journal:  World J Hepatol       Date:  2012-05-27

3.  Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

4.  Over-expression of cyclin D1 regulates Cdk4 protein synthesis.

Authors:  M A Parker; N G Deane; E A Thompson; R H Whitehead; S K Mithani; M K Washington; P K Datta; D A Dixon; R D Beauchamp
Journal:  Cell Prolif       Date:  2003-12       Impact factor: 6.831

Review 5.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

6.  The tumor suppressor LKB1 antagonizes WNT signaling pathway through modulating GSK3β activity in cell growth of esophageal carcinoma.

Authors:  Kai Liu; Yue Luo; Hui Tian; Kai-Zhong Yu; Jin-Xian He; Wei-Yu Shen
Journal:  Tumour Biol       Date:  2014-02

7.  Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.

Authors:  A I Robles; M L Rodriguez-Puebla; A B Glick; C Trempus; L Hansen; P Sicinski; R W Tennant; R A Weinberg; S H Yuspa; C J Conti
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

8.  p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.

Authors:  G Busatto; Y H Shiao; A R Parenti; R Baffa; A Ruol; M Plebani; M Rugge
Journal:  Mol Pathol       Date:  1998-04

9.  Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.

Authors:  Karen A Rossi; Jay A Markwalder; Steven P Seitz; Chong-Hwan Chang; Sarah Cox; Michael D Boisclair; Leonardo Brizuela; Stephen L Brenner; Pieter F W Stouten
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

Review 10.  Chemoprevention of esophageal squamous cell carcinoma.

Authors:  Gary D Stoner; Li-Shu Wang; Tong Chen
Journal:  Toxicol Appl Pharmacol       Date:  2007-03-15       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.